Mastodon

Velgammavit (Solution) Instructions for Use

Marketing Authorization Holder

Velpharm, LLC (Russia)

ATC Code

A11DB (Vitamin B1 in combination with vitamins B6 and/or B12)

Dosage Form

Bottle Rx Icon Velgammavit Solution for intramuscular injection

Dosage Form, Packaging, and Composition

Solution for intramuscular injection

1 ml
Pyridoxine hydrochloride 50 mg
Thiamine hydrochloride 50 mg
Cyanocobalamin 0.5 mg

2 ml – ampoules (10 pcs.) – cardboard packs – By prescription
2 ml – ampoules (5 pcs.) – cardboard packs – By prescription

Clinical-Pharmacological Group

B complex vitamins

Pharmacotherapeutic Group

Vitamins; vitamin B1 and its combinations with vitamins B6 and B12; vitamin B1 in combination with vitamins B6 and/or B12

Pharmacological Action

Complex of B vitamins.Thiamine (B1), Pyridoxine (B6) and Cyanocobalamin (B12) are neurotropic substances and play a special role as coenzymes in the intermediate metabolism occurring in the central and peripheral nervous system.

Like other vitamins, they are essential nutritional components that the body is unable to synthesize on its own.

Therapeutic use of vitamins B1, B6 and B12 compensates for the often existing insufficient dietary intake of vitamins, ensuring the presence of the necessary amount of coenzymes in the body. The use of B vitamins as a complex increases their therapeutic efficacy, as the efficacy of the combination exceeds that of the individual components.

The therapeutic use of these vitamins in various diseases of the nervous system aims, on the one hand, to compensate for an existing deficiency (possibly due to an increased body demand caused directly by the disease) and, on the other hand, to stimulate natural mechanisms aimed at recovery.

Furthermore, the indirect analgesic effect of the B vitamin complex has a beneficial effect on the therapeutic outcome.

Pharmacokinetics

After oral administration, Thiamine undergoes dose-dependent transport, the mechanism of which is dual in nature: active absorption at concentrations up to 2 µmol/L and passive diffusion at concentrations above 2 µmol/L. Phosphorylation of thiamine occurs in the liver. T1/2 is about 4 hours.

The human body contains about 30 mg of thiamine. Given its rapid metabolism, it is eliminated within 4-10 days.

Pyridoxine is absorbed very quickly, mainly in the upper intestine, and is eliminated within a maximum of 2-5 hours. Performing the coenzyme function requires phosphorylation of pyridoxine. Pyridoxine in the phosphorylated form (pyridoxal phosphate) is almost 80% bound to plasma proteins.

The human body contains about 40-150 mg. 1.7-3.6 mg is excreted in urine per day.

Cyanocobalamin is absorbed from the gastrointestinal tract through 2 mechanisms: 1) release under the action of gastric juice and rapid binding to intrinsic factor; 2) passive diffusion through the intestinal epithelium independent of intrinsic factor.

At doses greater than 1.5 µg, the latter mechanism plays a significant role. In patients with B12-deficiency anemia, reabsorption after oral administration is approximately 1% from 100 µg and above.

Excess cyanocobalamin accumulates in the liver.

Cyanocobalamin is excreted from the liver with bile into the intestine and is largely reabsorbed during enterohepatic circulation. The metabolic rate of Cyanocobalamin per day is 2.5 µg.

Indications

As part of complex therapy for the following neurological diseases: neuritis and neuralgia – trigeminal neuralgia; facial nerve paresis; intercostal neuralgia; pain syndrome caused by spinal diseases (lumbosciatica, plexopathy, radicular syndrome caused by degenerative changes of the spine); herpes zoster; neuropathic pain caused by polyneuropathy including diabetic and alcoholic).

ICD codes

ICD-10 code Indication
B02.2 Herpes zoster with other complications of the nervous system
G50.0 Trigeminal neuralgia
G51 Disorders of facial nerve
G54 Lesions of nerve roots and plexuses
G58.0 Intercostal neuropathy
G60 Hereditary and idiopathic neuropathy
G61 Inflammatory polyneuropathy
G62.1 Alcoholic polyneuropathy
G63.2 Diabetic polyneuropathy
M42 Spinal osteochondrosis
M47 Spondylosis
M54.1 Radiculopathy
M54.3 Sciatica
M54.4 Lumbago with sciatica
M79.2 Neuralgia and neuritis, unspecified
ICD-11 code Indication
1E91.40 Acute trigeminal neuropathy due to herpes zoster
1E91.41 Acute herpetic geniculate ganglionitis
1E91.4Y Other specified acute cranial nerve neuropathy due to herpes zoster
1E91.4Z Acute cranial nerve neuropathy due to herpes zoster, unspecified
1E91.Z Herpes zoster, unspecified
8B82.0 Trigeminal neuralgia
8B88.Z Lesions of facial nerve, unspecified
8B93.Z Radiculopathy, unspecified
8B9Z Diseases of nerve roots or plexuses, unspecified
8C01.Z Inflammatory polyneuropathy, unspecified
8C03.0 Diabetic polyneuropathy
8C12.0 Intercostal neuropathy
8C2Y Other specified hereditary neuropathy
8C4Z Disorders of nerve roots, plexuses or peripheral nerves, unspecified
8D44.0 Alcoholic polyneuropathy
8E4A.1 Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system
FA85.Z Defects of vertebral end-plates, unspecified
FA8Z Degenerative disease of spine, unspecified
FB56 Specified soft tissue diseases, not elsewhere classified
ME84.20 Lumbago with sciatica
ME84.3 Sciatica
1E91.3 Herpes zoster with involvement of the central nervous system
1D02.1 Viral myelitis

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Take orally 1 single dose 3 times/day. The duration of treatment is determined by the doctor and averages 1-1.5 months. Dose adjustment is recommended for therapy lasting more than 4 weeks.

Intramuscularly administer 1 single dose 1 time/day until acute symptoms are relieved. After symptom reduction or in case of moderate disease severity, administer 1 single dose 1-3 times a week for 2-3 weeks.

For maintenance therapy, for relapse prevention or continuation of the ongoing course of treatment, oral administration in the appropriate dosage form is recommended. The duration of treatment is determined individually by the doctor.

Adverse Reactions

From the immune system very rarely – hypersensitivity reactions, such as sweating, tachycardia.

Allergic reactions very rarely – itching, urticaria, anaphylactic shock.

From the digestive system: frequency not established – nausea, vomiting, diarrhea, abdominal pain.

From the nervous system frequency not established – long-term use (>6-12 months) of vitamin B6 at a daily dose >50 mg may cause peripheral sensory neuropathy.

Contraindications

Children under 18 years of age; hypersensitivity to the active substances of the combination.

Use in Pregnancy and Lactation

Use during pregnancy and lactation (breastfeeding) is not recommended due to the high content of vitamins.

Pediatric Use

The drug is contraindicated for use in children and adolescents under 18 years of age

Special Precautions

If signs of peripheral sensory neuropathy (paresthesia) appear, it is necessary to adjust the dose and, if necessary, discontinue the use of the medicinal product.

When administering vitamin B12, the clinical picture, as well as laboratory parameters in funicular myelosis or pernicious anemia, may lose their specificity.

Drug Interactions

When used concomitantly with levodopa, pyridoxine may reduce the antiparkinsonian effect of levodopa.

Concomitant use of pyridoxine antagonists (e.g., isoniazid, hydralazine, penicillamine, or cycloserine) may increase the requirement for pyridoxine.

Thiamine is inactivated by fluorouracil. Fluorouracil competitively inhibits the phosphorylation of thiamine to thiamine pyrophosphate.

Antacids reduce the absorption of thiamine.

“Loop” diuretics, e.g., furosemide, may block tubular reabsorption, thus enhancing the excretion of thiamine during long-term use, leading to a decrease in thiamine blood levels.

Intake of alcohol and black tea leads to reduced absorption of thiamine.

Beverages containing sulfites (e.g., wine) enhance the degradation of thiamine.

Storage Conditions

Store at 2°C (36°F) to 8°C (46°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS